In the same year, anecdotal evidence regarding the efficacy of this combination approach was published by Chong et al. They reported on a 35-year old male with relapsed DLBCL treated with a CD19 CAR (4.1BB costimulatory domain) who showed progression within one month after CAR-T cell infusion. Here, CD19 is linked to diffuse large B-cell lymphoma.